Skip to main content
Top
Published in: BMC Infectious Diseases 1/2005

Open Access 01-12-2005 | Research article

Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species

Authors: Ming-Fang Cheng, Yun-Liang Yang, Tzy-Jyun Yao, Chin-Yu Lin, Jih-Shin Liu, Ran-Bin Tang, Kwok-Woon Yu, Yu-Hua Fan, Kai-Sheng Hsieh, Monto Ho, Hsiu-Jung Lo

Published in: BMC Infectious Diseases | Issue 1/2005

Login to get access

Abstract

Background

Invasive fungal infections, such as candidemia, caused by Candida species have been increasing. Candidemia is not only associated with a high mortality (30% to 40%) but also extends the length of hospital stay and increases the costs of medical care. Sepsis caused by Candida species is clinically indistinguishable from bacterial infections. Although, the clinical presentations of the patients with candidemia caused by Candida albicans and non-albicans Candida species (NAC) are indistinguishable, the susceptibilities to antifungal agents of these species are different. In this study, we attempted to identify the risk factors for candidemia caused by C. albicans and NAC in the hope that this may guide initial empiric therapy.

Methods

A retrospective chart review was conducted during 1996 to 1999 at the Veterans General Hospital-Taipei.

Results

There were 130 fatal cases of candidemia, including 68 patients with C. albicans and 62 with NAC. Candidemia was the most likely cause of death in 55 of the 130 patients (42.3 %). There was no significant difference in the distribution of Candida species between those died of candidemia and those died of underlying conditions. Patients who had one of the following conditions were more likely to have C. albicans, age ≧ 65 years, immunosuppression accounted to prior use of steroids, leukocytosis, in the intensive care unit (ICU), and intravascular and urinary catheters. Patients who had undergone cancer chemotherapy often appeared less critically ill and were more likely to have NAC.

Conclusion

Clinical and epidemiological differences in the risk factors between candidemia caused by C. albicans and NAC may provide helpful clues to initiate empiric therapy for patients infected with C. albicans versus NAC.
Literature
1.
go back to reference Jarvis WR: Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis. 1995, 20: 1526-1530.CrossRefPubMed Jarvis WR: Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis. 1995, 20: 1526-1530.CrossRefPubMed
2.
go back to reference Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT: Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol. 1997, 18: 369-375.CrossRefPubMed Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT: Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol. 1997, 18: 369-375.CrossRefPubMed
3.
go back to reference Leleu G, Aegerter P, Guidet B: Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care. 2002, 17: 168-175. 10.1053/jcrc.2002.35815.CrossRefPubMed Leleu G, Aegerter P, Guidet B: Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care. 2002, 17: 168-175. 10.1053/jcrc.2002.35815.CrossRefPubMed
4.
go back to reference Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med. 1988, 148: 2642-2645. 10.1001/archinte.148.12.2642.CrossRefPubMed Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med. 1988, 148: 2642-2645. 10.1001/archinte.148.12.2642.CrossRefPubMed
5.
go back to reference Tortorano AM, Caspani L, Rigoni AL, Biraghi E, Sicignano A, Viviani MA: Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect. 2004, 57: 8-13. 10.1016/j.jhin.2004.01.017.CrossRefPubMed Tortorano AM, Caspani L, Rigoni AL, Biraghi E, Sicignano A, Viviani MA: Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect. 2004, 57: 8-13. 10.1016/j.jhin.2004.01.017.CrossRefPubMed
6.
go back to reference Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F: Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999, 28: 1071-1079.CrossRefPubMed Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F: Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999, 28: 1071-1079.CrossRefPubMed
7.
go back to reference Cheng MF, Yu KW, Tang RB, Fan YH, Yang YL, Hsieh KS, Ho M, Lo HJ: Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis. 2004, 48: 33-37. 10.1016/j.diagmicrobio.2003.08.002.CrossRefPubMed Cheng MF, Yu KW, Tang RB, Fan YH, Yang YL, Hsieh KS, Ho M, Lo HJ: Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis. 2004, 48: 33-37. 10.1016/j.diagmicrobio.2003.08.002.CrossRefPubMed
8.
go back to reference Colombo AL, Nucci M, Salomao R, Branchini ML, Richtmann R, Derossi A, Wey SB: High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis. 1999, 34: 281-286. 10.1016/S0732-8893(99)00042-5.CrossRefPubMed Colombo AL, Nucci M, Salomao R, Branchini ML, Richtmann R, Derossi A, Wey SB: High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis. 1999, 34: 281-286. 10.1016/S0732-8893(99)00042-5.CrossRefPubMed
9.
go back to reference Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, Baughman WS, Reingold AL, Rothrock GA, Pfaller MA, Pinner RW, Hajjeh RA: The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999, 29: 1164-1170. 10.1086/313450.CrossRefPubMed Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, Baughman WS, Reingold AL, Rothrock GA, Pfaller MA, Pinner RW, Hajjeh RA: The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999, 29: 1164-1170. 10.1086/313450.CrossRefPubMed
10.
go back to reference Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ: Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother. 2000, 44: 747-751. 10.1128/AAC.44.3.747-751.2000.CrossRefPubMedPubMedCentral Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ: Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother. 2000, 44: 747-751. 10.1128/AAC.44.3.747-751.2000.CrossRefPubMedPubMedCentral
11.
go back to reference Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ: Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol. 2004, 25: 60-64.CrossRefPubMed Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ: Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol. 2004, 25: 60-64.CrossRefPubMed
12.
go back to reference Yang YL, Cheng HH, Lo HJ: In vitro activity of voriconazole against Candida species isolated in Taiwan. Int J Antimicrob Agents. 2004, 24: 294-296. 10.1016/j.ijantimicag.2004.01.014.CrossRefPubMed Yang YL, Cheng HH, Lo HJ: In vitro activity of voriconazole against Candida species isolated in Taiwan. Int J Antimicrob Agents. 2004, 24: 294-296. 10.1016/j.ijantimicag.2004.01.014.CrossRefPubMed
13.
go back to reference Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996, 100: 617-623. 10.1016/S0002-9343(95)00010-0.CrossRefPubMed Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996, 100: 617-623. 10.1016/S0002-9343(95)00010-0.CrossRefPubMed
14.
go back to reference Redding SW, Kirkpatrick WR, Dib O, Fothergill AW, Rinaldi MG, Patterson TF: The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist. 2000, 20: 178-181.CrossRefPubMed Redding SW, Kirkpatrick WR, Dib O, Fothergill AW, Rinaldi MG, Patterson TF: The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist. 2000, 20: 178-181.CrossRefPubMed
15.
go back to reference Krcmery V, Barnes AJ: Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002, 50: 243-260. 10.1053/jhin.2001.1151.CrossRefPubMed Krcmery V, Barnes AJ: Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002, 50: 243-260. 10.1053/jhin.2001.1151.CrossRefPubMed
16.
go back to reference Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997, 24: 1122-1128.CrossRefPubMed Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997, 24: 1122-1128.CrossRefPubMed
17.
go back to reference Kralovicova K, Spanik S, Oravcova E, Mrazova M, Morova E, Gulikova V, Kukuckova E, Koren P, Pichna P, Nogova J, Kunova A, Trupl J, Krcmery V: Fungemia in cancer patients undergoing chemotherapy versus surgery: risk factors, etiology and outcome. Scand J Infect Dis. 1997, 29: 301-304.CrossRefPubMed Kralovicova K, Spanik S, Oravcova E, Mrazova M, Morova E, Gulikova V, Kukuckova E, Koren P, Pichna P, Nogova J, Kunova A, Trupl J, Krcmery V: Fungemia in cancer patients undergoing chemotherapy versus surgery: risk factors, etiology and outcome. Scand J Infect Dis. 1997, 29: 301-304.CrossRefPubMed
18.
go back to reference Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995, 20: 115-125.CrossRefPubMed Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995, 20: 115-125.CrossRefPubMed
19.
go back to reference Nikawa H, Egusa H, Makihira S, Nishimura M, Ishida K, Furukawa M, Hamada T: A novel technique to evaluate the adhesion of Candida species to gingival epithelial cells. Mycoses. 2003, 46: 384-389. 10.1046/j.0933-7407.2003.00912.x.CrossRefPubMed Nikawa H, Egusa H, Makihira S, Nishimura M, Ishida K, Furukawa M, Hamada T: A novel technique to evaluate the adhesion of Candida species to gingival epithelial cells. Mycoses. 2003, 46: 384-389. 10.1046/j.0933-7407.2003.00912.x.CrossRefPubMed
20.
go back to reference Yang YL, Cheng HH, Ho YA, Hsiao CF, Lo HJ: Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan. J Microbiol Immunol Infect. 2003, 36: 187-191.PubMed Yang YL, Cheng HH, Ho YA, Hsiao CF, Lo HJ: Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan. J Microbiol Immunol Infect. 2003, 36: 187-191.PubMed
21.
go back to reference Fatkenheuer G, Buchheidt D, Cornely OA, Fuhr HG, Karthaus M, Kisro J, Leithauser M, Salwender H, Sudhoff T, Szelenyi H, Weissinger F: Central venous catheter (CVC)-related infections in neutropenic patients – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003, 82 (Suppl 2): S149-57. 10.1007/s00277-003-0769-z. Epub@2003 Sep 9.: S149-S157.CrossRefPubMed Fatkenheuer G, Buchheidt D, Cornely OA, Fuhr HG, Karthaus M, Kisro J, Leithauser M, Salwender H, Sudhoff T, Szelenyi H, Weissinger F: Central venous catheter (CVC)-related infections in neutropenic patients – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003, 82 (Suppl 2): S149-57. 10.1007/s00277-003-0769-z. Epub@2003 Sep 9.: S149-S157.CrossRefPubMed
22.
go back to reference Salvaggio MR, Pappas PG: Current Concepts in the Management of Fungal Peritonitis. Curr Infect Dis Rep. 2003, 5: 120-124.CrossRefPubMed Salvaggio MR, Pappas PG: Current Concepts in the Management of Fungal Peritonitis. Curr Infect Dis Rep. 2003, 5: 120-124.CrossRefPubMed
23.
go back to reference Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, Diekema DJ: In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis. 2004, 48: 201-205. 10.1016/j.diagmicrobio.2003.09.008.CrossRefPubMed Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, Diekema DJ: In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis. 2004, 48: 201-205. 10.1016/j.diagmicrobio.2003.09.008.CrossRefPubMed
Metadata
Title
Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species
Authors
Ming-Fang Cheng
Yun-Liang Yang
Tzy-Jyun Yao
Chin-Yu Lin
Jih-Shin Liu
Ran-Bin Tang
Kwok-Woon Yu
Yu-Hua Fan
Kai-Sheng Hsieh
Monto Ho
Hsiu-Jung Lo
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2005
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-5-22

Other articles of this Issue 1/2005

BMC Infectious Diseases 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.